TrialThe British journal of dermatology2022

Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study.

Megan N Landis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.